Summary
This is a 2025 clinical practice guideline from the Korean Diabetes Association providing evidence-based recommendations for diabetes diagnosis and management in the Korean healthcare context. The guideline synthesises current scientific evidence to inform clinical decision-making across pharmacological and non-pharmacological treatment strategies. As a consensus document, it represents expert opinion on optimal care pathways for both type 1 and type 2 diabetes patients in the Korean population.
UK applicability
Whilst developed for Korean clinical practice, evidence-based elements such as glycaemic targets, medication algorithms, and complication screening protocols may have comparative relevance to UK diabetes management; however, direct application should account for differences in healthcare infrastructure, medication availability, and population characteristics between the two health systems.
Key measures
Clinical recommendations across diabetes management domains including glycaemic control targets, medication selection, dietary intervention, physical activity, and monitoring protocols
Outcomes reported
The study presents updated clinical practice recommendations for diabetes diagnosis, management, pharmacological and non-pharmacological interventions, and complication screening. It synthesises evidence-based guidance for healthcare providers managing patients with type 1 and type 2 diabetes.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.